Cargando…
Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395133/ https://www.ncbi.nlm.nih.gov/pubmed/22811702 http://dx.doi.org/10.1155/2012/827534 |
_version_ | 1782237938618204160 |
---|---|
author | Bijelic, Lana Sugarbaker, Paul H. Stuart, O. Anthony |
author_facet | Bijelic, Lana Sugarbaker, Paul H. Stuart, O. Anthony |
author_sort | Bijelic, Lana |
collection | PubMed |
description | Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m(2); subsequent 24 received 60 or 70 mg/m(2). The mean PCI was 21 ± 7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18 ± 2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m(2) appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed. |
format | Online Article Text |
id | pubmed-3395133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33951332012-07-18 Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients Bijelic, Lana Sugarbaker, Paul H. Stuart, O. Anthony Gastroenterol Res Pract Research Article Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m(2); subsequent 24 received 60 or 70 mg/m(2). The mean PCI was 21 ± 7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18 ± 2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m(2) appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed. Hindawi Publishing Corporation 2012 2012-07-03 /pmc/articles/PMC3395133/ /pubmed/22811702 http://dx.doi.org/10.1155/2012/827534 Text en Copyright © 2012 Lana Bijelic et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bijelic, Lana Sugarbaker, Paul H. Stuart, O. Anthony Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title_full | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title_fullStr | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title_full_unstemmed | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title_short | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
title_sort | hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395133/ https://www.ncbi.nlm.nih.gov/pubmed/22811702 http://dx.doi.org/10.1155/2012/827534 |
work_keys_str_mv | AT bijeliclana hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients AT sugarbakerpaulh hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients AT stuartoanthony hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients |